Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Halozyme Therapeutics (HALO)

NASDAQ: HALO · Biotechnology · San Diego, CA

Our rating: Positive

Positive reaffirmed at $103.63, moderate conviction, November 6, 2026.

Breaks if: The positive lean inverts if trailing twelve-month revenue growth decelerates below 15% — a signal that partner drug attrition or pricing pressure is biting the royalty line — or if free cash flow margin falls below 35% for two consecutive reported quarters, indicating that the platform's cash-conversion edge is narrowing rather than durable. Either condition within the next twelve months would force a reassessment toward Neutral or Cautious.

Key figures

Market value$10.4B
Revenue, last 12 months$1.8B
Net income, last 12 months$485M
Free cash flow, last 12 months$886M
Price to earnings21.5×
Free cash flow yield8.5%
Dividend yield0.0%
Operating margin37.4%
Return on equity216.4%
Beta to the S&P 5000.62
Volatility, annualized43.0%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$493M39.2%$2.01$255M
June 30, 2026$481M47.7%$1.90$237M
March 31, 2026$377M42.2%$1.22$176M
December 31, 2025$452M51.6%$-1.12$218M
September 30, 2025$354M22.1%$1.43$176M
June 30, 2025$326M40.8%$1.33$98M
March 31, 2025$265M35.2%$0.93$153M
December 31, 2024$298M29.5%$1.06$175M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

28 ledger entries and 66 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.